Optimizing PARP Inhibitor Outcomes in Cancer Therapy: Focus on Biomarkers of Homologous Recombination Repair

The rapid pace in the evolution of knowledge regarding how cancer develops and best approaches to treatment pose challenges to the medical community. This educational activity will review the deleterious effects of DNA damage, specifically the science of homologous recombination deficiency, and how it contributes to the development of cancer. Approved and expanded indications for the PARP inhibitors will be explained, including evidence for their use based on biomarkers, efficacy, and safety data. The activity will include real-life case scenarios demonstrating how genetic testing data can be used to develop treatment plans that illustrate these concepts.

Monday, Dec. 4
11:30 a.m. - 1 p.m. PT (2:30 - 4 p.m. ET)

Symposium Location: Room 157,100 Level, Anaheim Convention Center – North

Come early! Seating is limited and provided on a first-come, first-served basis.

Can't make it to Anaheim? Tune into the Free Live Webinar Broadcast.
Registration is required for the webinar.


Christine M. Walko

Christine M. Walko, PharmD, FCCP, BCOP, Activity Chair
Senior Member, Department of Pathology, Precision Medicine Team Lead
Moffitt Cancer Center
Tampa, Florida

Christine M. Walko, PharmD, FCCP, BCOP graduated with her PharmD degree from Duquesne University in Pittsburgh, Pennsylvania, and completed a pharmacy practice residency at the Medical College of Virginia/VCU in Richmond, Virginia, and a hematology/oncology specialty residency at the University of North Carolina (UNC). She stayed at UNC to complete a 2-year academic oncology fellowship focused on drug metabolism and translational research before taking an Assistant Professor position at UNC in the Division of Pharmacotherapy and Experimental Therapeutics until being recruited to Moffitt Cancer Center in January 2014 to assist with starting the institution’s first Precision Medicine Program. Dr. Walko is now a Senior Member in the Department of Pathology at Moffitt Cancer Center, Program Leader for Precision Medicine and an Attending on the Precision Medicine Clinical Service. She is also a Co-Chair for the ASCO TAPUR trial Molecular Tumor Board (MTB) and variant expert for the nationwide SWOG Precision Medicine trial focused on the clinical utility of Molecular Tumor Boards in Community Oncology Practices. Her research focus is on optimizing drug therapy using pharmacogenomics and pharmacokinetics to personalize intravenous and oral anticancer therapy for patients with cancer.

Jing-Yi Jeannie Chern

Jeannie Chern, MD, ScM
Associate Member, Gynecologic Oncologist
H. Lee Moffitt Cancer Center
Associate Professor, Gynecologic Oncologist
University of South Florida Morsani College of Medicine
Tampa, Florida

Jeannie Chern, MD, ScM is an Associate Member in Gynecologic Oncology at Moffitt Cancer Center. She completed Residency in Obstetrics and Gynecology at the University of South Florida and Gynecologic Oncology Fellowship at New York University. She is the lead for genetics education and tumor board. In addition, she is the assistant program director for the GYN oncology fellowship. Her clinical focus is personalization and comprehensive care for women with gynecologic cancers, with a special interest in the surgical management of advanced malignancies. Dr. Chern’s research is involved in understanding genetic factors associated with gynecologic malignancies to improve and guide patient care.

Target Audience

The target audience for this educational activity includes pharmacists, physicians, physician assistants, and nurse practitioners who practice in hospitals and health systems.

Learning Objectives

  • Discuss the mechanisms of homologous recombination deficiency as they relate to the development of cancer.
  • Apply evidence-based recommendations in parallel with genomic/molecular diagnostic testing results that inform the use of PARP inhibitors in treating cancer.
  • Develop an interprofessional treatment plan taking into account patient-specific and cancer-specific factors, including biomarker testing data.


  • 11:30 a.m. – Welcome and Introductions
    Christine M. Walko
  • 11:35 a.m. – Background on HRD, PARP Inhibitors, and Assays in Cancer
    Christine M. Walko
  • 12 p.m. – Patient Case – PARP Inhibitor Initiation and Monitoring Based on HRD Results
    Jeannie Chern
  • 12:25 p.m. – Future Directions and Current Opportunities for Optimizing HRD in Practice
    All Faculty
  • 12:50 p.m. – Faculty Discussion, Questions and Answers
    All Faculty

Accredited for CPE and CME

ACPE #: 0204-0000-23-408-L01-P
CE Credit: 1.5 contact hours (0.15 CEUs)
Activity Type: Application-based
Activity Fee: No charge

To Claim CE for the webinar, enter the CE code announced during the activity and complete the evaluation.



ACPE logo black and white The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
ACCME logo The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Health-System Pharmacists designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ASHP Advantage logo Provided by ASHP.
Supported by an educational grant from AstraZeneca.
Supported by an educational grant from Merck.
For questions and assistance to participate, contact us.